Discontinued — last reported Q4 '21
Nucor Short-Term Borrowings increased by 9.8% to $134.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 16.3%, from $160.00M to $134.00M. Over 5 years (FY 2020 to FY 2025), Short-Term Borrowings shows an upward trend with a 16.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
High levels may indicate a reliance on short-term credit markets for operational cash flow, which can increase liquidity risk.
Short-term borrowings consist of debt obligations that are due within one year, excluding the current portion of long-te...
Varies by industry; pharmaceutical firms often maintain access to short-term credit for operational flexibility.
short_term_borrowings| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $100.69M | $102.74M | $107.72M | $86.52M | $100.51M | $64.65M | $49.08M | $29.32M | $35.94M | $119.21M | $130.00M | $168.51M | $213.75M | $225.00M | $160.00M | $157.00M | $136.00M | $122.00M | $134.00M |
| QoQ Change | — | +2.0% | +4.9% | -19.7% | +16.2% | -35.7% | -24.1% | -40.3% | +22.6% | +231.7% | +9.1% | +29.6% | +26.8% | +5.3% | -28.9% | -1.9% | -13.4% | -10.3% | +9.8% |
| YoY Change | — | — | — | — | -0.2% | -37.1% | -54.4% | -66.1% | -44.4% | +142.9% | +343.5% | — | +494.8% | +88.7% | +23.1% | -6.8% | -36.4% | -45.8% | -16.3% |